2022 年猴痘疫情期间特考韦瑞玛治疗的种族和社会经济公平性，美国纽约州纽约市。
Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA.
出版信息
Emerg Infect Dis. 2023 Nov;29(11):2353-2357. doi: 10.3201/eid2911.230814. Epub 2023 Oct 5.
Abstract
We assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox emergency; 32.4% received tecovirimat. Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other). Future public health emergency responses must prioritize institutional and structural racism mitigation.
摘要
我们评估了 2022 年美国纽约市 3740 名猴痘患者的特考韦瑞玛特治疗公平性；32.4%的患者接受了特考韦瑞玛特治疗。按种族/族裔划分的治疗率分别为 38.8%（白人）、31.3%（黑人/非裔美国人）、31.0%（西班牙裔/拉丁裔）和 30.1%（亚洲/太平洋岛民/其他）。未来的公共卫生应急响应必须优先考虑减轻制度和结构性种族主义。
Zotero 插件